What is valenTx?
Headquartered in Maple Grove, Minnesota, valenTx operates at the intersection of medical technology and metabolic health. The company specializes in the engineering of implantable devices designed to provide a non-surgical alternative for patients suffering from severe obesity and associated metabolic disorders, such as type-II diabetes. By focusing on less invasive procedures, valenTx aims to improve patient outcomes, reduce recovery times, and lower the overall cost of care within the healthcare ecosystem. Its market position is defined by its commitment to clinical rigor and the development of breakthrough technologies that address significant, well-recognized medical needs.
How much funding has valenTx raised?
valenTx has raised a total of $25.2M across 3 funding rounds:
Series A
$772K
Series B
$20.3M
Debt
$4.1M
Series A (2004): $772K, investors not publicly disclosed
Series B (2009): $20.3M led by Covidien Ventures, Kaiser Permanente Ventures, SV Health Investors, Affinity Capital Management, Sapient Capital Management, and EDF Ventures
Debt (2014): $4.1M supported by SV Life Sciences and EDF Ventures
Key Investors in valenTx
SV Health Investors
A specialist investment firm backing innovative health care and life science companies, partnering with founders to provide capital and sector expertise from early growth through scale.
EDF Ventures
A leading venture capital firm focused on early-stage healthcare companies developing breakthrough technologies to address large, well-recognized medical problems.
Kaiser Permanente Ventures
A national leader in strategic venture investing in healthcare, focusing on advancing innovation that provides clear value for patients, providers, and delivery systems.
What's next for valenTx?
Looking ahead, valenTx is poised to leverage its recent financing to scale its operational capabilities and advance its clinical trial programs. The strategic focus remains on achieving key regulatory milestones and expanding the reach of its implantable device portfolio. As the company transitions from development to broader commercialization, the support of its seasoned investor base will be critical in navigating the complexities of the medical device market. The firm's ability to sustain its growth trajectory will depend on its continued success in demonstrating the long-term efficacy and safety of its metabolic treatments, ultimately aiming to establish a new standard of care for patients worldwide.
See full valenTx company page
